Bioxyne (CRYPTO: BXN) — Company Overview, News & Financial Data
Bioxyne is an Australian life sciences and healthcare company specializing in the manufacture, wholesale, and distribution of investigational medicines, novel therapeutic goods, and consumer health products.
Bioxyne
Bioxyne is an Australian life sciences and healthcare company specializing in the manufacture, wholesale, and distribution of investigational medicines, novel therapeutic goods, and consumer health products. Operating through its wholly owned subsidiary Breathe Life Sciences, the company manufactures Good Manufacturing Practice certified medicinal cannabis, MDMA, and psilocybin products for clinical trials and authorised prescribers. Additionally, it supplies proprietary direct-to-consumer health products, including probiotics, food-grade mushroom products, and cannabidiol supplements, under brands such as Dr Watson and PCC across Australia, the United Kingdom, Europe, Japan, and the United States.
Snapshot
Operations
Products and/or services of Bioxyne
- Medicinal Cannabis Manufacturing and Wholesale: Contract Good Manufacturing Practice manufacturing, importing, exporting, and wholesale distribution of medicinal cannabis final dose forms and active pharmaceutical ingredients to licensed clinics, pharmacies, and brand sponsors across Australia, Europe, and Australasia.
- Psychotropic Investigational Medicines: TGA-licensed Good Manufacturing Practice final dose form manufacturing and international distribution of investigational MDMA and psilocybin products, serving clinical trial sponsors and authorised healthcare prescribers for novel mental health treatment protocols.
- Consumer Health Products: Retail and direct-to-consumer distribution of over-the-counter health, wellness, and novel food offerings, including cannabidiol supplements, nicotinamide adenine dinucleotide formulations, food-grade mushrooms, and wellness products sold globally under proprietary brands.
- Contract Pharmaceutical Manufacturing and Sponsorship: End-to-end contract drug manufacturing, regulatory sponsorship, and supply chain management services for third-party clients, producing final dose form medicines and active pharmaceutical ingredients for over 200 commercial medicine brands.
- European and UK Wholesale Services: Importation, regulatory compliance, and wholesale distribution operations facilitating entry and supply of medicinal cannabis and novel healthcare products into key European markets, including the United Kingdom, Germany, and the Czech Republic.
- Probiotic Health Formulations: Development and global commercialisation of proprietary probiotic strains and finished health products, including specialized oral formulations, providing gastrointestinal and immune system support through established retail and healthcare distribution networks.
Bioxyne executive team
- Mr. Samuel WatsonCEO, MD & Executive Director
- Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICDCFO & Company Secretary
- Mr. Jason HineCOO & Executive Director
- Macdarragh O'NeillHead of Production of GMP & Director of BLS Wholesalers Pty